Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HQK-1004 + Valganciclovir in EBV+ Lymphoid Malignancies
NCT00992732Phase 2Terminated
- Sponsor
- HemaQuest Pharmaceuticals, Inc.
- Start
- May 2010
- Primary completion
- Nov 2010
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of arginine butyrate in lymphoid malignancy, lymphoproliferative disorder (LPD), sponsored by HemaQuest Pharmaceuticals, Inc.. Started May 2010; status: terminated.
02
Drugs
arginine butyrate
03
Conditions
lymphoid malignancylymphoproliferative disorder (LPD)
Beyond the preview
Go deeper on NCT00992732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00992732.